Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment

Abstract

Several studies have explored the potential of targeting tumor angiogenesis in cancer treatment. Anti-angiogenesis monotherapy, which reduces blood vessel numbers, may still hold some promise in cancer treatment, but thus far it has only provided a modest effect on overall survival benefits. When combined with standard chemotherapies, some significant improvements in cancer therapy have been reported. However, anti-angiogenesis therapies can have undesirable effects, including the induction of tumor hypoxia and reduction of delivery of chemotherapeutic drugs. Interestingly, anti-angiogenic drugs, such as bevacizumab, when used at lower doses, can actually induce vascular normalization (that is, they improve blood vessel function and flow) and potentially enhance co-administrated chemotherapeutic drug delivery. Unfortunately, vascular normalization is a difficult approach to apply in clinical settings. Thus, there is an urgent need to explore new approaches for modulating the tumor vasculature. Here, we explore how vascular promotion strategies (which enhance blood vessel numbers and leakiness) may be optimized for combination therapies as an alternative option for cancer treatment.

Nucleolar and spindle‐associated protein 1 is a tumor grade correlated prognosis marker for glioma patients

“…In addition, NUSAP1 expression was correlated with retinal neovascularization in mouse models of oxygen‐induced retinopathy . As angiogenesis is a rate‐limiting step which guarantees sufficient nutrients and oxygen supply in tumor growth, targeting NUSAP1 may hold promise in preventing tumor progression in this respect. However, similar results remain to be replicated in human gliomas.…”

Oral aktive Peptide: Gibt es ein Patentrezept?

“…[185] Als Konsequenz auf das Einfügen von polaren Aminosäuren geht die intestinale Permeabilitätk omplett verloren, welche aber mithilfe des LPCM-Ansatzes wiederhergestellt werden konnte. [85c, 115] 115,187]…”

Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms

“…The de novo prevention of angiogenesis, followed by silent tumor death, is the most appealing anti-cancer strategy [55]. In breast cancer, hypoxia-inducible factor (HIF-1) α is regarded as a crucial regulator of angiogenesis.…”